The estimated Net Worth of Matthew Plunkett is at least $5.59 million dollars as of 4 March 2016. Matthew Plunkett owns over 10,000 units of Nkarta stock worth over $3,788,339 and over the last 12 years Matthew sold NKTX stock worth over $1,804,221.
Sign up
Matthew Plunkett NKTX stock SEC Form 4 insiders trading
Matthew has made over 28 trades of the Nkarta stock since 2014, according to the Form 4 filled with the SEC. Most recently Matthew sold 10,000 units of NKTX stock worth $5,900 on 4 March 2016.
The largest trade Matthew's ever made was selling 170,000 units of Nkarta stock on 21 March 2014 worth over $634,100. On average, Matthew trades about 19,934 units every 19 days since 2012. As of 4 March 2016 Matthew still owns at least 590,084 units of Nkarta stock.
You can see the complete history of Matthew Plunkett stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Matthew Plunkett's mailing address?
Matthew's mailing address filed with the SEC is C/O NKARTA, INC., 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Nkarta
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani et Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
What does Nkarta do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What does Nkarta's logo look like?
Complete history of Matthew Plunkett stock trades at CTI BioPharma Corp et Nkarta
Nkarta executives and stock owners
Nkarta executives and other stock owners filed with the SEC include:
-
Paul J. Hastings,
CEO, Pres & Director -
Dr. Nadir Mahmood Ph.D.,
Chief Financial & Bus. Officer -
Dr. Alicia J. Hager,
Chief Legal Officer & Corp. Sec. -
Dr. Kanya Rajangam,
Chief Medical Officer -
Greg Mann,
VP of Public Affairs and Investor Relations -
Dr. James Trager Ph.D., Ph.D.,
Chief Scientific Officer -
Dr. Ralph Brandenberger Ph.D.,
Sr. VP of Technical Operations -
Zachary Scheiner,
-
Leone D Patterson,
-
David Shook,
See Remarks -
George Vratsanos,
-
Michael Dybbs,
-
Ali Behbahani,
-
Nadir Mahmood,
President -
Laura Shawver,
Director -
Kanya Rajangam,
Chief Medical Officer -
Fouad Oscar Azzam,
Director -
Matthew Plunkett,
Chief Financial Officer -
James Trager,
Chief Scientific Officer -
James E Deerfield Mgmt Iv, ...,
-
Capital Management, L.P.Ra ...,
-
Capital Management, L.P.Kol...,
-
Holdings A/S Novo,
10% owner -
Simeon George,
-
Plc Gsk,
Director -
Angela Thedinga,
-
Ralph Brandenberger,
Chief Technical Officer -
Alicia J. Hager,
Chief Legal Officer -
Paul J Hastings,
Chief Executive Officer -
Capital Management, L.P.Ra ...,
-
Tiba Aynechi,
Director -
Alyssa Levin,
See Remarks